Skip to Main Content

INFORMATION FOR

Study of Safety and of the Mechanism of BLZ945 in ALS Patients

Conditions

Diseases of the Nervous System

Phase II

What is the purpose of this trial?

This is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.

  • Trial with
    Novartis Pharmaceuticals
  • Start Date
    02/28/2022
  • End Date
    04/05/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/11/2022
  • Study HIC
    #2000026495